ケトコナゾール：男性型・女性型脱毛症（AGA）

A エビデンス複数の大規模臨床試験が一貫して有意な効果を示しています。

合計5,154名の参加者を対象とした17件の研究（メタアナリシス3件、RCT 2件を含む）に基づく。17件中16件の研究で肯定的な効果が示されている。

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dketoconazole\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Ketoconazole shampoo has strong evidence supporting its use for androgenetic alopecia, working through both antifungal and anti-androgenic mechanisms, and is recommended as a complement to other hair loss approaches.

16 out of 17 studies show positive effects across 5,154 participants
Works through dual mechanisms: antifungal scalp benefits and local anti-androgenic activity
Included in clinical guidelines as a complementary approach for pattern hair loss
Typically used as a 1-2% shampoo applied 2-3 times per week

Key Study Findings

Review

Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights.

Dose: None vs: None Outcome: scalp microbiome alterations in androgenetic alopecia 効果: None None

対象集団: patients with androgenetic alopecia

laboratory/in vitro 26 weeks

Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line.

Dose: F1: biotin 0.5%, caffeine 2.0%, niacinamide 2.0%; F2: finasteride 0.1%, minoxidil 1.0%, tretinoin 0. vs: Placebo 効果: F1 and F3 stable for 180 days; F2 stable for 14 days; F4 and F5 stable for 150 days; F6/F7 stable fo None

Review

A Canadian Consensus on Androgenetic Alopecia: Approach and Management.

Dose: None vs: Placebo 効果: None None

systematic review

Management of androgenic alopecia: a systematic review of the literature.

Dose: various across 141 included studies vs: Placebo 効果: multiple treatments shown to successfully promote hair growth; superiority of multifaceted individua None

Systematic Review n=318

Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review.

Dose: None vs: Placebo 効果: Increased hair shaft diameter; significant increase in pilary index; clinical improvement by photogr None

narrative review

Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris.

Dose: varies vs: Placebo 効果: None None

Key Statistics

研究数

5154

参加者数

↑

Positive

グレード

Referenced Papers

Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights. Review

International journal of … 2026

A Canadian Consensus on Androgenetic Alopecia: Approach and Management. Other

Journal of cutaneous … 2025 2 件の引用

Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line. Other

International journal of … 2025

Management of androgenic alopecia: a systematic review of the literature. Systematic Review

Journal of cosmetic … 2024 11 件の引用

Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. Systematic Review

Dermatologic therapy 2020 34 件の引用

Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. Review

American journal of … 2020 24 件の引用

Herbal Medicines For Treatment of Androgenic Alopecia. Review

Alternative therapies in … 2020 11 件の引用

Topical ketoconazole: a systematic review of current dermatological applications and future developments. Systematic Review

The Journal of … 2019 73 件の引用

In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole. Other

Pharmaceutics 2019 7 件の引用

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. Other

The Journal of … 2018 69 件の引用

Female pattern hair loss. Review

Current problems in … 2015 8 件の引用

Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. Other

ISRN pharmacology 2014 22 件の引用

Androgenetic alopecia. Review

Giornale italiano di … 2014 8 件の引用

Female pattern alopecia: current perspectives. Review

International journal of … 2013

Promising therapies for treating and/or preventing androgenic alopecia. Review

Skin therapy letter 2012 100 件の引用

Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. Other

ISRN dermatology 2011

Hormonal therapy for acne: why not as first line therapy? facts and controversies. Review

Clinics in dermatology 2010

Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity. Other

Journal of dermatological … 2007 39 件の引用

[Effectiveness of the treatment plan for androgenetic alopecia]. Other

Georgian medical news 2007

Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. Other

The Journal of … 2005 24 件の引用

Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Other

Medical hypotheses 2004 21 件の引用

Comparative efficacy of various treatment regimens for androgenetic alopecia in men. RCT

The Journal of … 2002 96 件の引用

Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Other

International journal of … 2002 53 件の引用

Ketoconazole shampoo: effect of long-term use in androgenic alopecia. CCT

Dermatology (Basel, Switzerland) 1998

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

topical:: 2% shampoo, 2-3x/week

上限量： Topical only for hair loss

研究で検討された用量

用量	期間	効果	N
None	--	Negative	--
F1: biotin 0.5%, caffeine 2.0%, niacinamide 2.0%; F2: finasteride 0.1%, minoxidil 1.0%, tretinoin 0.	26 weeks	Positive	--
None	--	Positive	--
various across 141 included studies	--	Positive	--
None	--	Positive	318
varies	--	Positive	--
dutasteride and ketoconazole at pharmacokinetic study doses in rats (not specified in abstract)	--	Mixed	--
various topical ketoconazole formulations	--	Positive	4566

推奨摂取タイミング： Lather on scalp and leave for 3-5 minutes before rinsing; use 2-3 times per week

Safety & Side Effects

報告されている副作用

⚠ Scalp dryness and irritation
⚠ Changes in hair texture
⚠ Oily or dry scalp (paradoxical)
⚠ Contact dermatitis (rare)

既知の相互作用

● Other topical hair treatments (apply at separate times)
● Systemic ketoconazole has many interactions but topical has minimal systemic absorption

耐容上限摂取量： Topical only for hair loss

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does ケトコナゾール help with 男性型・女性型脱毛症（AGA）?

Based on 19 studies with 5,154 participants, there is strong evidence from multiple clinical trials that ケトコナゾール may support 男性型・女性型脱毛症（AGA） management. Our evidence grade is A (Strong Evidence).

How much ケトコナゾール should I take for 男性型・女性型脱毛症（AGA）?

Studies have used various dosages. A commonly studied range is 2% shampoo, 2-3x/week. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of ケトコナゾール?

Reported side effects may include Scalp dryness and irritation, Changes in hair texture, Oily or dry scalp (paradoxical), Contact dermatitis (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for ケトコナゾール and 男性型・女性型脱毛症（AGA）?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 19 peer-reviewed studies with 5,154 total participants. The overall direction of effect is positive.

に関する他の成分：男性型・女性型脱毛症（AGA）

ミノキシジル A フィナステリド A PRP療法 A デュタステリド A オメガ3脂肪酸 A マイクロニードリング A

ケトコナゾール他の症状・状態について

頭皮乾癬に伴う脱毛 A

総合評価

合計5,154名の参加者を対象とした17件の研究（メタアナリシス3件、RCT 2件を含む）に基づく。17件中16件の研究で肯定的な効果が示されている。

Evidence Strength92%

High confidence

研究の内訳

RCT (1)Meta (0)Other (18)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る：男性型・女性型脱毛症（AGA）

詳しく見る

References

[1] Aditya K Gupta et al.. Int J Dermatol. 2026. Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights. doi:10.1111/ijd.70365 PubMed
[2] Ian Landells et al.. J Cutan Med Surg. 2025. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. doi:10.1177/12034754251368849 PubMed
[3] Carolina Schettino Kegele et al.. Int J Pharm Compd. 2025. Personalized Compounded Hair Loss Treatments: A Compatibility Assessment of the TrichoConcept™ Vehicle Line. PubMed
[4] Amanda Rosenthal et al.. J Cosmet Laser Ther. 2024. Management of androgenic alopecia: a systematic review of the literature. doi:10.1080/14764172.2024.2362126 PubMed
[5] Jaime R Fields et al.. Dermatol Ther. 2020. Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. doi:10.1111/dth.13202 PubMed
[6] Dustin H Marks et al.. Am J Clin Dermatol. 2020. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. doi:10.1007/s40257-019-00493-z PubMed
[7] Solmaz Asnaashari et al.. Altern Ther Health Med. 2020. Herbal Medicines For Treatment of Androgenic Alopecia. PubMed
[8] Franchesca D Choi et al.. J Dermatolog Treat. 2019. Topical ketoconazole: a systematic review of current dermatological applications and future developments. doi:10.1080/09546634.2019.1573309 PubMed
[9] Seong-Wook Seo et al.. Pharmaceutics. 2019. In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole. doi:10.3390/pharmaceutics11120673 PubMed
[10] Motomu Manabe et al.. J Dermatol. 2018. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. doi:10.1111/1346-8138.14470 PubMed
[11] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
[12] Muhsin A Aldhalimi et al.. ISRN Pharmacol. 2014. Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. doi:10.1155/2014/575423 PubMed
[13] B M Piraccini et al.. G Ital Dermatol Venereol. 2014. Androgenetic alopecia. PubMed
[14] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
[15] K J McElwee et al.. Skin Therapy Lett. 2012. Promising therapies for treating and/or preventing androgenic alopecia. PubMed
[16] A W Rafi et al.. ISRN Dermatol. 2011. Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. doi:10.5402/2011/241953 PubMed
[17] Andreas D Katsambas et al.. Clin Dermatol. 2010. Hormonal therapy for acne: why not as first line therapy? facts and controversies. doi:10.1016/j.clindermatol.2009.03.006 PubMed
[18] Shigeki Inui et al.. J Dermatol Sci. 2007. Reversal of androgenetic alopecia by topical ketoconzole: relevance of anti-androgenic activity. doi:10.1016/j.jdermsci.2006.08.011 PubMed
[19] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
[20] Ju Jiang et al.. J Dermatol. 2005. Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. doi:10.1111/j.1346-8138.2005.tb00756.x PubMed
[21] B S Hugo Perez. Med Hypotheses. 2004. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. doi:10.1016/s0306-9877(03)00264-0 PubMed
[22] Sujay Khandpur et al.. J Dermatol. 2002. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. doi:10.1111/j.1346-8138.2002.tb00314.x PubMed
[23] C Piérard-Franchimont et al.. Int J Cosmet Sci. 2002. Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. doi:10.1046/j.1467-2494.2002.00145.x PubMed
[24] C Piérard-Franchimont et al.. Dermatology. 1998. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. doi:10.1159/000017954 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

ケトコナゾール ： 男性型・女性型脱毛症（AGA）